peptidefix

Peptides / Sermorelin / United States

Sermorelin in the United States

Legal status, what it is, and the listed suppliers in the United States that list it.

Legal status in the United States

No current FDA label. The openFDA drug label database holds no current label for sermorelin (checked 2026-09-22).

As understood at 2026-09-22. Verify with the FDA.

What Sermorelin is

Sermorelin is the first 29 amino acids of growth hormone-releasing hormone, the shortest fragment that still triggers the pituitary to release growth hormone. It was developed as a medicine for growth hormone deficiency in children and marketed under the name Geref; there is no current FDA label for it. In Australia it is a prescription-only substance.

Full Sermorelin page: targets and research →

Listed suppliers in the United States

7 of the 10 suppliers we list in the United States list Sermorelin. Listed, not endorsed: each row is the supplier’s own stated terms.

Core Peptides United States Products are for laboratory, research or analytical purposes only, and are not for human consumption. Direct Peptides United States All products are sold strictly for laboratory research use only and are not for human or animal consumption. Direct Peptides is a chemical supplier, not a compounding pharmacy or 503A/503B facility. Licensed Peptides United States Supplied strictly for laboratory research use only. Not intended for human consumption, veterinary use, therapeutic applications, or diagnostic use. No dosing instructions are provided. Nationwide Peptides United States For Research Use Only. Products are not intended for human or animal consumption, ingestion, injection, or any form of administration. Peak Lab Peptides United States All products on this site are for research and development use only. Products are not for human consumption of any kind. Protide Health United States All products are supplied for laboratory research only and are not for human or animal consumption, medical use, veterinary use, or any therapeutic, diagnostic, or clinical purpose. Sigma Compounds United States Products are for research and development purposes only and are not for human consumption.

Clinical Research

Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone
Neyzi O, Yordam N, Ocal G, et al. (1993). Acta Paediatrica. human 43 prepubertal children aged 4 to 19 with growth hormone deficiency of hypothalamic origin, randomised to three treatment groups for 6 months
Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration
Wilton P, Chardet Y, Danielson K, et al. (1993). Acta Paediatrica. human 30 healthy men aged 19 to 43, intravenous and intranasal administration
Intranasal administration of growth hormone-releasing hormone(1-29)-NH2 in children with growth hormone deficiency: effects on growth hormone secretion and growth
Hummelink R, Sippell WG, Benoit KG, et al. (1993). Acta Paediatrica. human 8 short prepubertal children with growth hormone deficiency, 6-month intranasal pilot study
Effects of long-term growth hormone releasing hormone 1-29 in significantly short children
Grunt JA, Schwartz ID, Buchanan C, Howard CP (1995). Acta Paediatrica. human 7 children with idiopathic short stature and normal growth hormone levels, treated up to 24 months